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Abstract
Blood clotting is a precise cascade engineered to form a clot with temporal and spatial control. Current control of blood
clotting is achieved predominantly by anticoagulants and thus inherently one-sided. Here we use a pair of nanorods (NRs)
to provide a two-way switch for the blood clotting cascade by utilizing their ability to selectively release species on their
surface under two different laser excitations. We selectively trigger release of a thrombin binding aptamer from one
nanorod, inhibiting blood clotting and resulting in increased clotting time. We then release the complementary DNA as an
antidote from the other NR, reversing the effect of the aptamer and restoring blood clotting. Thus, the nanorod pair acts as
an on/off switch. One challenge for nanobiotechnology is the bio-nano interface, where coronas of weakly adsorbed
proteins can obscure biomolecular function. We exploit these adsorbed proteins to increase aptamer and antidote loading
on the nanorods.
Citation: de Puig H, Cifuentes Rius A, Flemister D, Baxamusa SH, Hamad-Schifferli K (2013) Selective Light-Triggered Release of DNA from Gold Nanorods
Switches Blood Clotting On and Off. PLoS ONE 8(7): e68511. doi:10.1371/journal.pone.0068511
Editor: Maxim Antopolsky, University of Helsinki, Finland
Received May 1, 2013; Accepted May 30, 2013; Published July 2 , 2013
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was funded by the National Science Foundation grant# DMR #0906838. http://www.nsf.gov/. HdP was supported by a fellowship from La
Caixa Foundation (Spain). http://obrasocial.lacaixa.es/laCaixaFoundation/home_en.html. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: schiffer@mit.edu
¤a Current address: Massachusetts Institutes of Technology Lincoln Laboratory, Lexington, Massachusetts, United States of America
¤b Current address: Lawrence Livermore National Laboratory, Livermore, California, United States of America
Introduction
Nature has engineered the blood coagulation cascade to initiate
clotting with temporal and spatial precision. However, our ability
to artificially manipulate blood clotting is not nearly as precise. In
wound healing and surgery, blood clotting must be controlled for
patient safety, and is achieved predominantly via the anticoagu-
lants heparin, warfarin and others. However, anticoagulants suffer
major limitations, causing them to rank as the leading cause of
death in adverse drug reactions in therapeutic use in the US [1,2].
This is due to the fact that these anticoagulants can only inhibit the
cascade, so their means of control is inherently one-sided.
Furthermore, many anticoagulants suffer additional limitations.
Heparin, the most prevalently used anticoagulant, is a polydisperse
polymer that inhibits several species in the clotting cascade, but
not a single specific factor. The main source of heparin is the
intestines of livestock such as pigs, but the risk of contamination is
significant and can be fatal [3–5]. More importantly, these
anticoagulants have no specific antidote, and reversing their effect
is predominantly achieved by clearance, which can vary greatly
among people. Thus, introducing an inhibitor and a specific
antidote with spatial and temporal control is highly desirable.
Nanotechnology has great potential as an enabling technology
for biology because nanoparticles can be designed to interface
directly with biomolecules. In particular, external laser excitation
of nanoparticles can trigger payload release [6,7], so nanoparticles
can act as handles for controlling biological processes. Gold
nanorods (NRs) have gained considerable interest for therapeutic
applications because they can be selectively excited where tissue is
transparent to release multiple species that can impact complex
processes [6,8–10] so they have many advantages for controlling
blood clotting.
Thrombin inhibitors are of great interest as candidates for
anticoagulants because thrombin, which cleaves fibrinogen into
fibrin to form the clot, is at the apex of the clotting cascade
[11,12]. We used ssDNA thrombin binding aptamers (TBA) to
inhibit thrombin and consequently coagulation. We then used
complementary DNA as an antidote because it can reverse TBA’s
effect by base-pairing with it (Figure 1a). Selective excitation of two
different NRs to release TBA and its antidote enables the pair to
act as an on/off switch for coagulation.
Results and Discussion
TBA has been identified by SELEX to bind and inhibit
thrombin [13]. TBA folds into a double G-quartet and binds to
exosite I, so it inhibits thrombin activity by preventing fibrinogen
binding [14–16]. Thrombin inhibition results in an increase in
blood clotting time, tplasma. We verified TBA’s ability to inhibit
clotting by measuring its effect on tplasma in a thrombin test [17].
Blood with no TBA was normalized as tplasma =1.0. Increasing
TBA concentration increased tplasma (Figure 1b), indicating that
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TBA inhibited thrombin and consequently the blood coagulation
cascade.
We verified that the antidote could reverse TBA’s effect. As
antidote:TBA was increased from 0:1 to 2:1, tplasma started at 4.4
and decreased (Figure 1c). Thus, antidote could successfully inhibit
TBA by forming a double strand with it and preventing it from
folding into the G-quartet structure necessary for thrombin
binding (Figure 1a) [17]. DGbinding (TBA-thrombin) =235.6 kJ/
mol, where DGbinding (TBA-antidote) =267 kJ/mol [15,18], so
TBA’s affinity for antidote is stronger than for thrombin. Also, we
have previously demonstrated that in solution, the antidote can
displace thrombin from TBA and that the TBA-antidote hybrid
remains bound for several hours in the presence of thrombin [16].
Blood clotting time was restored to its original value at 1:1
TBA:antidote, indicating excess antidote was not needed to
reverse TBA’s function [19,20].
Cetyltrimethylammonium bromide (CTAB)-coated gold parti-
cles that absorbed at two distinct wavelengths were synthesized
[21–23]. Rod-shaped nanorods (NRs) with an aspect ratio (AR)
= 3.7 and DH=45 nm had a longitudinal surface plasmon
resonance (LSPR) at 763 nm (Figure 2a, c, e). Bone-shaped
‘‘nanobones’’ (NBs) with AR=4.8 and DH=55 nm had a LSPR at
1065 nm (Figure 2b, d, e). Because NRs and NBs exhibited
distinct absorption features, selective excitation by fs-pulsed lasers
was possible. 800 nm irradiation of a NR-NB mixture resulted in
melting of the NRs only, seen by a decrease of the LSPR at
800 nm (Figure 2h). Melting induced the NRs to change shape to
spheres, which shifts and decreases their LSPR [24]. The LSPR at
1100 nm did not change, indicating that NBs were not melted
because 800 nm coincides with a minimum in their absorption
(Figure 2b, blue dotted line). Likewise, NRs do not absorb at
1100 nm (Figure 2a, red dotted line), so 1100 nm irradiation
resulted in a decrease of the NB LSPR but did not affect the NR
LSPR, indicating selective melting of the NBs (Figure 2i) [6].
Melting of the NRs and NBs separately was confirmed (Figure S1).
While DNA conjugation to gold NRs can be achieved by thiol-
Au bonding [25], we used protein coronas because they exhibit
high payload capacity while still enabling triggered release via laser
excitation of the NR. Coronas of human serum (HS) were formed
around the particles [26] and NR-coronas were loaded with TBA
(NR-HS-TBA), NB-coronas with antidote (NB-HS-antidote). The
NR-HS-TBA had DH=662625 nm, and NB-HS-antidote
DH=938650 nm (Figure 2e, Figure S2), indicating that a corona
contains multiple particles. However, NR and NB LSPRs were not
significantly shifted (black, Figure 2a, b), so excitation at 800 and
1100 nm was still feasible. Zeta potentials for NR-HS-TBA and
NB-HS-anti were negative because HS is negative (Figure 2f) [27].
DNA loading was 674674 TBA/NR and 13076255 antidote/NB
(Figure 2g).
Laser irradiation could trigger DNA release. NB-HS-TBA were
irradiated at 1100 nm and their LSPR decreased, confirming NB
melting (Figure 3a). Released antidote quantified by fluorescence
was [anti] = 12965 nM or 430617 nM (Figure 3a, inset). NR-
HS-TBA were irradiated at 800 nm and their LSPR decreased,
confirming melting, and released [TBA] = 663623 nM or 22368
released TBA/NR (Figure 3b, inset). Introducing released TBA to
Figure 1. TBA and antidote affect coagulation in whole human blood. a) Schematic of coronas made from human serum (HS) loaded with
NRs and TBA (NR-HS-TBA) + coronas loaded with NBs and antidote (NB-HS-antidote). 800 nm laser irradiation melts the NRs, triggering release of TBA
from the coronas, which inhibits thrombin and causes blood coagulation times to increase. Following this, 1100 nm laser irradiation melts the NBs,
triggering release of the DNA antidote from the corona. The antidote forms a double-stranded hybrid with TBA, thus restoring thrombin activity and
blood coagulation. Fluorescently labeled TBA has a sequence of 5’ GGTTGGTGTGGTTGG-TMR 3’. The fluorescently labeled antidote has the
complementary sequence 5’ CCAACCACACCAACC-FAM 3’. Clotting time (tplasma) for a thrombin test using 10 nM thrombin measured by a
coagulometer with b) TBA, for c) 500 nM TBA + varying antidote from [anti] = 0 to 1000 nM (anti/TBA = 0 to 2.0).
doi:10.1371/journal.pone.0068511.g001
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blood resulted in a tplasma increase to 1.61 (Figure 3c, red).
Comparing the effect to free TBA, this change in tplasma would
result from a free TBA concentration of [TBA] = 609 nM
(Figure 3d, red circle and dashed line). Thus, released TBA was
,94% functional in coagulation, showing that there was minimal
damage from the laser or steric hindrance by other released
corona species. These experiments show that laser irradiation can
release TBA from coronas on NRs, and released TBA is largely
functional and can impact blood coagulation.
Using coronas for TBA loading has several advantages over
covalent attachment. Compared to NRs conjugated to thiolated
TBA (thiol-TBA), coronas had higher loadings and resulted in
greater released DNA/NR. Analogous experiments performed
with covalently attached thiol-TBA released less DNA/NR
(released [thiol-TBA] = 14606108 nM, or 130610 released
thiol-TBA/NR), and released TBA was less functional (64%, blue
circle, Figure 3e, and Figure S3). Furthermore, NR concentrations
necessary to achieve this impact on tplasma were extremely high
(11 nM), resulting in optically dense solutions that required long
irradiation times (,30 min). This in combination with the fact
that the TBA was directly attached to the NR could be responsible
for the lower activity due to laser damage [28]. Thus, using
coronas for loading can reduce irradiation time and subsequently
improve both yield and functionality of DNA. The coronas do
have a broad size distribution (.35%), and it is expected that they
have a distribution in the number of NRs or NBs per corona, and
also amount of DNA per corona. This could potentially result in a
distribution of the amount of DNA released per corona and also in
the time it takes for the DNA to be released from the corona.
However, the net benefits of the increased payload and the
improved functionality of the released payload outweigh these
disadvantages.
We selectively released TBA from the NRs and antidote from
the NBs to inhibit and then restore blood clotting. First, a NR-HS-
TBA + NB-HS-antidote mixture (black, Figure 4a) was exposed to
800 nm irradiation. The 800 nm LSPR decreased but the
1100 nm LSPR was unaffected, confirming selective melting
(red, Figure 4a). TMR fluorescence in the supernatant due to
released TBA increased while FAM fluorescence due to the
antidote did not increase as much, illustrating that the NRs
preferentially released payload (red, Figure 4b). Quantifying
release showed that 800 nm irradiation released 10764 nM
TBA (252610 released TBA/NR), but only 1.360.2 nM antidote.
Released species introduced to blood resulted in an increase in
tplasma to 1.73 (Figure 4c), indicating that released TBA inhibited
thrombin and thus blood coagulation. Next, the NR-HS-TBA +
NR-HS-antidote mixture was irradiated at 1100 nm. The
1100 nm LSPR decreased, confirming NB melting (blue,
Figure 4a). FAM fluorescence increased, indicating that
152618 nM antidote was released (692682 released antidote/
NB) (blue, Figure 4b), while 63 nM TBA was released. The effect
on coagulation was tplasma =0.88, demonstrating that released
antidote could reverse the effect of TBA and restore coagulation to
its original tplasma (Figure 4c). 1100 nm irradiation alone on NR-
HS-TBA + NB-HS-anti (Figure S4) did not significantly change
tplasma (0.98, Figure 4c), showing that antidote release alone does
not affect coagulation. To test whether HS release affects
coagulation, NR-HS were prepared without TBA and mixed
Figure 2. Gold nanoparticles synthesized and loaded for triggered release. Absorption spectra of a) NRs, NR-HSA-TBA coronas (LSPR max
= 777 nm), b) NB, NB-HSA-antidote (LSPR max = 1093 nm). c) TEM image of NRs, scale bar = 20 nm, d) TEM image of NBs, scale bar = 100 nm, e) DH
(DLS) of NRs, NR-HS-TBA, NBs, NB-HS-antidote, indicating that a corona contains multiple not a single NR or NB, but multiple ones. f) Zeta potential of
NRs, NR-HS-TBA =29.8 mV, NBs, NB-HS-antidote =210.1 mV g) Quantified DNA payloads of NR-HS-TBA (674674 TBA/NR), NB-HS-antidote
(13076255 antidote/NB). h) mixture of NR-CTAB + NB-CTAB before (black) and after (red) 800 nm irradiation. i) NR-CTAB + NB-CTAB before (black)
and after (red) 1100 nm irradiation.
doi:10.1371/journal.pone.0068511.g002
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with NB-HS-anti. 800 nm irradiation resulted in no significant
change in tplasma (1.1), confirming that the presence of TBA was
necessary to affect coagulation. Finally, we verified that the
presence of NR-HS-TBA + NB-HS-anti mixture with blood did
not affect tplasma (0.86).
Timescales for melting NRs with an ultrafast laser pulse are on
the order of ps [29,30], and release and binding timescales are
expected to be on the order of ns-ms. Overall, these timescales are
more rapid than the coagulation experiment (,20–200 s). The
irradiation of the sample does take time (15min) due to the fact
that the laser spot size is smaller than the sample. Timescales of
minutes seem reasonable since the potential application of surgery
has on operating timescale that is much longer. Also, the
irradiation time could potentially be decreased by increasing the
illumination area.
This work demonstrates that external laser excitation can
selectively release a thrombin inhibitor and its antidote, allowing
the NR/NB pair to act as an on/off switch for blood clotting.
Furthermore, the use of protein coronas for loading and release of
payloads from NRs opens up new possibilities for selective release
applications, and it can be exploited for controlling blood clotting.
Materials and Methods
Synthesis and characterization of gold NRs
Gold nanorods (NRs) were synthesized by a single surfactant
non-seed-mediated growth method in 20 mL batches [21,23,31]
and gold nanobones (NBs) were synthesized in 50 ml batches by a
double surfactant seed-mediated growth method [22]. TEM
analysis showed that the NRs measured 34.6 6 6.1 nm6 9.5 6
2.2 nm, with an AR of 3.7 and the NBs measured 59.4 6 13.7 nm
612.5 6 2.4 nm, with an AR of 4.8. All reagents were purchased
from Sigma Aldrich, except from sodium chloride that was from
Mallinckrodt. Excess reagents were removed by centrifuging the
particles at 12000 rcf, 15 min and resuspended in MilliQ water.
Afterwards, 1 nM NRs were further centrifuged at 12000 rcf for
15 min and resuspended in 5 mM CTAB for storage.
Corona formation and loading
Coronas of human serum (HS) were formed around NRs and
NBs and loaded with either TBA or antidote using a previously
published combined loading approach [26]. Quantification of the
payload was achieved by heating the sample for 30 min and 90uC
and measuring the fluorescence spectroscopy of the supernatant.
Briefly, a 20 ml pellet of 10 nM NRs was resuspended in 1 ml of a
5 mM phosphate buffer solution, with 1 mM ssDNA and 5%
Figure 3. Release from NR- and NB-coronas and their comparison to covalently loaded NRs. a) Absorption spectrum of NB-HS-TBA before
(black) and after (red) 1100 nm irradiation, where [NB-HS-anti] = 0.3 nM, and released [anti] = 12965 nM (430617 anti released/NB). Inset:
fluorescence spectrum of released TBA before (black) and after (red) 1100 nm irradiation. b) Absorption spectrum of NR-HS-TBA before (black) and
after (red) 800nm irradiation where [NR-HS-TBA] = 2.9 nM, and released [TBA] = 663623 nM (22368 DNA released/NR). Inset: fluorescence spectrum
of released TBA before (black) and after (red) 800 nm irradiation, c) Effect of the released TBA in blood. Comparing normalized tplasma from released
TBA from the coronas [NR-HS-TBA] = 2.9 nM (red), where released [TBA] = 663623 nM in a clotting test. Supernatant of NR-HS-TBA with exposed to
no irradiation and added to blood is defined as tplasma = 1.0 (gray dotted line). A significant difference (p#0.05) from baseline tplasma is indicated with
a * (Table S1), d) tplasma (normalized) calibration curve of free TBA in a thrombin test (stars). Released TBA from NR-HS-TBA (red circle) and
extrapolated equivalent concentration (red dashed line). e) tplasma (normalized) calibration curve of free thiolated TBA (blue X’s). Released thiolated
TBA from NR-thiol-TBA (14606108 nM, blue square) and extrapolated equivalent concentration (blue dashed line).
doi:10.1371/journal.pone.0068511.g003
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sterile filtered human serum, followed by an overnight incubation
at 37uC, showing a loading of 674674 DNA/NR and 13076255
Anti/NB. Single stranded DNA (ssDNA) was purchased from
Integrated DNA Technologies and fluorescently labeled for
quantification with tetramethylrhodamine (TMR), or fluorescein
(FAM). The sequences used were 59 GGTTGGTGTGGTTGG-
TMR 39 (TBA) and 59 AACCAACACAACCAA-FAM 39 (anti).
Human serum was purchased from Sigma Aldrich.
Corona formation was confirmed by UV-VIS, which was
evidenced by a shift in the particle absorbance spectra, as well as
DLS and zeta potential measurements, which showed an increase
in the size of the particles and a change in the charge of the
solution, which was due to the presence of the serum proteins.
Selective release from NR-NB mixture
Laser irradiations were performed using pulsed femtosecond
light. For the 800 nm irradiation, the 532 nm output of a Q-
switched Nd:YLF laser (Empower, Spectra-Physics) was used to
pump a Ti:Sapphire regenerative amplifier (Spitfire, Spectra-
Physics), which amplifies the 82MHz output of a Ti:Sapphire
oscillator, producing 50–475 mJ light centered at 800 nm, with a
duration of 100 fs, a repetition rate of 1 kHz, and a spot size of
6 mm. The 1100 nm irradiation was achieved with a two-stage
BBO/KNbO3 optical parametric amplifier, pumped with a
800nm pulse (Coherent Legend USX:,25 fs, 1 kHz), producing
,13.6 mJ pulses, with a duration of ,45 fs, centered at 1100 nm.
The beam was focused to a spot size of ,100–120 mm. In a
typical experiment, 100 ml of the NR-NB mixture were irradiated
in a 363 mm quartz cuvette for 20 min. After irradiation, samples
were spun at 14000 rcf for 15 min, and the supernatants were
collected to quantify the DNA released and for blood clotting tests.
NP melting was confirmed by observing a decrease in their
absorbance spectra.
Blood clotting measurements
Plasma equivalent thrombin time was measured using a
Hemochron Signature Elite (ITC). In a typical experiment,
14.4 ml of the sample were mixed with 1.8 ml of 100 nM thrombin
and 1.8 ml of 1.37M NaCl, and incubated at 37uC for 10 min.
After mixing with 27 ml of citrated whole blood, samples were
loaded into APTT Citrate cuvettes to measure the blood clotting
time. Blood was purchased from Research Blood Components
(RBC) and used within 10 days. Functionality of the released TBA
from coronas was calculated as a percentage between the
measured increase of tplasma and the expected increase of tplasma
from the same concentration of free TBA based on free TBA
calibration curves.
Supporting Information
Figure S1 Melting the CTAB-NR and CTAB-NB: We
separately tested melting of the NR-CTAB (a) and the
NB-CTAB (b). We could observe that the NR-CTAB melted
after 800nm irradiation, and that the NB-CTAB could melt after
irradiation at 1100nm, as evidenced by the decrease in their
respective LSPR peaks.
(TIFF)
Figure S2 Size distribution of coronas measured by
DLS. a) NRs (red) and NR-HS-TBA coronas (green), b) NBs (red)
and NB-HS-antidote coronas (green).
(TIF)
Figure S3 Melting and release of thiolated TBA from
NRs. a) Absorbance and b) fluorescence plots from the release of
thiolated TBA bound covalently to the NRs. UV-VIS absorption
shows a decrease of the SPR after the 800nm irradiation (left).
Released thiolated TBA was quantified by fluorescence as
1460nM from 11.25nM NR-thiolated TBA (right), yielding
130.4 thiolated TBA released per NR.
(TIFF)
Figure S4 Effect of irradiation at 1100 nm. We irradiated
the NR-HS-TBA NB-HS-anti mixture (before irradiation in black)
at 1100nm. We observed melting of the NBs only (red line
Figure S2), as observed by the decrease of their SPR at 1100nm,
while the NRs were not melted. Inset shows the increase in
fluorescence of the antidote, where 216nM antidote and 4nM
TBA were released. The mixture had 0.37nM NB-HS-anti, and
0.40nM NR-HS-TBA.
(TIFF)
Table S1 Statistics for blood clotting tests. Two-tailed t-
tests were performed using Origin 6.1. We report here the p-values
of the samples that show significant differences. For each
Figure 4. Selective melting of NRs and NBs to switch blood
clotting off and on. NR-HS-TBA and NB-HS-antidote were mixed at a
ratio so that the TBA:antidote was 1:1. a) NR-HS-TBA + NB-HS-anti
mixture before (black) and after 800 nm irradiation (red), after 800 nm
and then 1100 nm irradiation (blue) b) fluorescence of released
supernatant before (black) and after 800 nm irradiation (red), and after
800 nm+1100 nm irradiation (blue). c) Normalized tplasma for samples
before irradiation (defined as 1.0, and used to compare the statistical
parameters of all samples) of mixture of NR-HS-TBA + NB-HS-antidote
with excitation at 800 nm (tplasma increases to 1.73), and
800 nm+1100 nm (tplasma restored to 0.88), demonstrating restoration
of clotting time. 1100 nm irradiation alone of the mixture NR-HS-TBA +
NB-HS-anti, showing no significant increase in clotting time. Irradiation
at 800 nm of NR-HS (without TBA) + NB-HS-anti showing no increase in
clotting time. To test the effect of the presence of the nanoparticles, HS-
NR-TBA+NB-HS-anti were not exposed to any irradiation in blood.
Significant differences (p#0.05) from baseline tplasma are indicated with
an * (Table S1).
doi:10.1371/journal.pone.0068511.g004
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experiment, the baseline (no laser irradiation) was compared with
the measured value of tplasma.
(PDF)
Text S1 Supporting Information Synthesis: Method for
loading thiolated TBA onto NRs by thiol chemistry.
(PDF)
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